Phase II Trial of Argon and Oxygen Ventilation After Cardiac Arrest to Reduce Brain Injury and Improve Recovery

What this Trial Is About

Researchers are investigating the use of argon gas mixed with oxygen as a treatment to reduce neurological and heart damage after cardiac arrest outside of the hospital. Preclinical studies in animals showed argon may protect cells and improve recovery following low oxygen events. The CardioPulmonary Resuscitation with Argon CPAr trial began as a phase I-II safety study and is now continuing as a phase II trial to evaluate argons effect on brain injury after cardiac arrest. In this randomized, controlled, single-blind study, patients who have been resuscitated from out-of-hospital cardiac arrest will receive ventilation with either a mixture of 70% argon and 30% oxygen or standard ventilation with 30% oxygen for four hours. Both groups will be treated according to established European resuscitation and intensive care guidelines. The study treatment lasts four hours, followed by monitoring over a six-month period to assess safety and clinical outcomes. Participants will be closely monitored during and after treatment with assessments including neurological function, heart function, brain injury markers, survival rates up to six months, and multiorgan function. Safety will be evaluated by recording any adverse events within one month. The main outcome focuses on neuronal preservation measured 48 hours after treatment. This comprehensive follow-up aims to understand argons potential impact on recovery after cardiac arrest over both the short and long term.

CardioPulmonary Resuscitation With Argon (CPAr) Trial